Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on PAG. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel dihalide-to-acid route eliminates toxic cyanide, offering cost-effective Repaglinide intermediate manufacturing with high purity.
Novel acid-catalyzed oxidation route for Dapagliflozin Impurity A. High purity reference standard synthesis for quality control. Cost-effective API intermediate manufacturing.
Patent CN113214169B reveals a mild, high-yield route for pyrazine intermediates. Discover cost-effective manufacturing strategies for pulmonary hypertension drugs.
Patent CN112321454B reveals a streamlined synthesis for Eltrombopag intermediates, offering significant cost reduction and scalable manufacturing for pharmaceutical supply chains.
Discover the advanced purification method for Dapagliflozin in patent CN109705075B. Achieve high purity without protecting groups, ensuring cost reduction and supply reliability.
Novel patent CN110305118B enables high-purity Empagliflozin production with simplified reduction steps ensuring supply chain stability and cost efficiency.
Novel patent CN108752184A offers eco-friendly SGLT2 intermediate synthesis. Reduces cost and waste. Reliable supplier for high-purity pharmaceutical intermediates.
Patent CN110922305A reveals a novel route for 5-bromo-2-chloro-4'-ethoxy diphenylmethane, eliminating ortho-impurities and ensuring high-purity API intermediates.
Patent CN116239552B reveals a magnesium-catalyzed route for empagliflozin intermediates. This method offers significant supply chain stability and cost reduction potential for pharmaceutical manufacturing.
Improved empagliflozin synthesis patent CN118271301A offers high purity and cost reduction for pharmaceutical intermediate manufacturing supply chains.
Patent CN108047163A reveals improved Repaglinide synthesis. Enhances yield and purity while reducing toxic solvent use for reliable supply chain.
Advanced synthesis of Empagliflozin intermediates via novel Grignard reduction. Superior isomer control and scalable manufacturing for global pharmaceutical supply chains.
This report analyzes patent CN104961715B for Dapagliflozin production offering reduced impurities and scalable manufacturing solutions for global pharmaceutical supply chains.
Patent CN109988161A details a telescoped synthesis for Empagliflozin, offering significant cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Novel Pummerer reaction method for sulfur-containing aryl carbon glycosides. Mild conditions, high yield, suitable for API intermediate manufacturing.
Patent CN1265650A reveals a novel double-protection strategy for synthesizing 6-amino-3-azabicyclo[3.1.0]hexane derivatives, offering superior stereoselectivity and cost-effective routes for quinolone antibiotic manufacturing.
Novel synthesis route for empagliflozin intermediates offering high purity and cost reduction in pharma manufacturing. Reliable supply chain for diabetes drug precursors ensures continuity.
Patent CN119613391B reveals ionic liquid extraction for empagliflozin purification offering high purity yield and reduced solvent consumption for scalable pharmaceutical manufacturing supply chains.
Novel patent CN117924259A details high-purity impurity synthesis for quality control offering scalable solutions for pharmaceutical supply chains and cost reduction.
Patent CN120554343A reveals new iron and palladium catalytic route. Improves yield and safety for empagliflozin manufacturing supply chain.